Two T1D Technology Leaders Partnering to Drive Innovation and Choice
Two leading innovators in the type 1 diabetes (T1D) space have announced a collaborative partnership aimed at enabling those with T1D to select favorite devices, knowing they all work together, even if made by different companies. The nonprofit company Tidepool announce that it is partnering with leading pump manufacturer Medtronic to create an interoperable automated […]
ADA Scientific Sessions Recap—Day #4: Simi Ahmed, Ph.D.
The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the immune therapy program at Breakthrough T1D, who highlights some of the important immune-based therapies and what they mean for the type 1 diabetes community:
ADA Scientific Sessions Recap—T1D Prevention Research: Jessica Dunne, Ph.D.
There was some really exciting T1D prevention research in day #3, and also screening for type 1 diabetes risk. Here is Jessica Dunne, Ph.D., senior director of the prevention portfolio, who gives a recap of day in T1D prevention research:
A New AP System by Tandem Shows Key Time-in-Range Benefits
A new artificial pancreas system that both doses and takes away insulin is showing critical benefits in helping those with type 1 diabetes maintain more consistent, and healthier, glucose levels. Two studies, shared this weekend, showed that the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology by Tandem® Diabetes Care resulted in more […]
ADA Scientific Sessions Recap—Day #3: Dan Finan, Ph.D.
There was some really amazing results out here in San Francisco! Here is Dan Finan, Ph.D., head of the Breakthrough T1D’s artificial pancreas and glucose control programs, to recap the day:
First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset
This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune therapy demonstrated a significant delay in the time to onset of type 1 diabetes (T1D) in high-risk relatives of people with the disease. A significant delay meaning 2+ years! This is the first ever study […]
ADA Scientific Sessions – The Second Day: Andrew Rakeman, Ph.D.
We’re at the 2019 American Diabetes Association Scientific Sessions, and there’s so much to learn! Here is the recap from Breakthrough T1D‘s assistant director for science, Andy Rakeman, Ph.D.:
Sanjoy Dutta, Ph.D.: The Beginning of the ADA Scientific Sessions
The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights beta cell replacement therapies. Happy viewing!
Breakthrough T1D Heads to ADA’s 79th Scientific Sessions
The American Diabetes Association’s (ADA) 79th Scientific Sessions is almost here! From June 7-11, in San Francisco, CA, scientists and healthcare professionals will gather at one of the largest conferences of diabetes researchers in the world. Breakthrough T1D researchers and Breakthrough T1D-funded scientists will also be there to hear first-hand and present new study results […]
Breakthrough T1D Urges Congress to Fund Diabetes Research
On June 4, Breakthrough T1D’s President & CEO Aaron J. Kowalski, Ph.D., testified before the U.S. House of Representatives Committee on Energy & Commerce, Health Subcommittee about Breakthrough T1D’s top legislative priority — securing a long-term renewal of the Special Diabetes Program (SDP) before it expires at the end of September. During the hearing, Dr. […]
